HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $66
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $27 to $66.
HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $27 to $66.